Scholarlink

<p><i>RUNX1A</i> is the shortest and least expressed of the <i>RUNX1</i> three main isoforms (A, B, C); despite this, the leukemogenic role of its overexpression has been clearly described. Several studies have shown <i>RUNX1A</i> involvement in different blood cancers and pilot observations in acute leukemia have been reported. In this context, we evaluated <i>RUNX1</i> isoforms expression in a cohort of acute myeloid leukemia (AML) patients, finding overexpression of <i>RUNX1A</i> and <i>RUNX1B</i>, with higher median levels in thrombocytopenic cases. No difference was observed for <i>RUNX1C</i>. <i>RUNX1A</i> overexpression is higher in more immature AML phenotypes. According to the mutational profile, <i>FLT3</i> internal tandem duplication (ITD) positive cases have the highest <i>RUNX1A</i> levels and the presence of <i>FLT3</i>-ITD was the only molecular variable able to influence <i>RUNX1A</i> expression. <i>RUNX1A</i> overexpression is disease-related, associated with a specific transcriptional profile, and reappears at relapse, with no clear kinetics except in <i>FLT3</i>-ITD cases. Overall, we demonstrate <i>RUNX1A</i> overexpression in AML and its association with the <i>FLT3</i>-ITD molecular subtype. Our data shed light on the dark side of <i>RUNX1</i> deregulation, paving the way for further investigations.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

RUNX1A isoform is overexpressed in acute myeloid leukemia and is associated with FLT3 internal tandem duplications

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年7月15日

查看全文
  • Cosimo Cumbo,
  • Francesco Tarantini,
  • Elisa Parciante,
  • Luisa Anelli,
  • Antonella Zagaria,
  • Giuseppina Biondi,
  • Mariano Francesco Caratozzolo,
  • Paola Orsini,
  • Nicoletta Coccaro,
  • Giuseppina Tota,
  • Immacolata Redavid,
  • Maria Rosa Conserva,
  • Angela Minervini,
  • Crescenzio Francesco Minervini,
  • Vito Pier Gagliardi,
  • Mario Delia,
  • Flaviana Marzano,
  • Claudia Telegrafo,
  • Sharon Natasha Cox,
  • Annalisa Natalicchio,
  • Bachir Balech,
  • Apollonia Tullo,
  • Mattia Gentile,
  • Francesco Giorgino,
  • Giorgina Specchia,
  • Pellegrino Musto,
  • Francesco Albano

摘要

RUNX1A is the shortest and least expressed of the RUNX1 three main isoforms (A, B, C); despite this, the leukemogenic role of its overexpression has been clearly described. Several studies have shown RUNX1A involvement in different blood cancers and pilot observations in acute leukemia have been reported. In this context, we evaluated RUNX1 isoforms expression in a cohort of acute myeloid leukemia (AML) patients, finding overexpression of RUNX1A and RUNX1B, with higher median levels in thrombocytopenic cases. No difference was observed for RUNX1C. RUNX1A overexpression is higher in more immature AML phenotypes. According to the mutational profile, FLT3 internal tandem duplication (ITD) positive cases have the highest RUNX1A levels and the presence of FLT3-ITD was the only molecular variable able to influence RUNX1A expression. RUNX1A overexpression is disease-related, associated with a specific transcriptional profile, and reappears at relapse, with no clear kinetics except in FLT3-ITD cases. Overall, we demonstrate RUNX1A overexpression in AML and its association with the FLT3-ITD molecular subtype. Our data shed light on the dark side of RUNX1 deregulation, paving the way for further investigations.